Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43851   clinical trials with a EudraCT protocol, of which   7283   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2012-001592-37
    Sponsor's Protocol Code Number:F02695_LP_2_05
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2012-06-26
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2012-001592-37
    A.3Full title of the trial
    Effect of 3-month treatment with F2695 (75mg OD) on improving functional recovery of patients with ischemic stroke. A Multicenter, Randomised, Double-blind, Parallel-group, Placebo-Controlled Study.
    Efecto del tratamiento con F2695 (75 mg una vez al día) durante 3 meses en la mejoría de la recuperación funcional de pacientes con accidente cerebrovascular isquémico. Estudio multicéntrico, aleatorizado, doble ciego, en grupos paralelos y controlado con placebo
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Trial is to assess the effect of 3-month treatment with F2695 on improving functional
    recovery after stroke. A study that will cover many study centres, and which will involve a random draw to decide whether placebo or active drug; neither the subject nor study doctor will know which of the two treatments are received.
    Este ensayo se hace para evaluar el efecto del tratamiento durante 3 meses con F2695 en la mejoría de la recuperación funcional después de un derrame cerebral. Un estudio que cubrirá muchos centros y en el cual se hará un sorteo al azar para decidir si le toca placebo o fármaco activo; ni el paciente ni el médico sabrán cual de los tratamientos se recibe.
    A.3.2Name or abbreviated title of the trial where available
    LIFE Study
    Estudio LIFE
    A.4.1Sponsor's protocol code numberF02695_LP_2_05
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorPierre Fabre Médicament; Represented by Institut de Recherche Pierre Fabre
    B.1.3.4CountryFrance
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportPierre Fabre Médicament
    B.4.2CountryFrance
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationIRPF - Pierre Fabre Innovation
    B.5.2Functional name of contact pointDr Mohammed ZAÏM
    B.5.3 Address:
    B.5.3.1Street AddressBP 13562 - 3 avenue Hubert Curien
    B.5.3.2Town/ cityTOULOUSE
    B.5.3.3Post codeF-3103
    B.5.3.4CountryFrance
    B.5.4Telephone number+33-(0)5-34-50-61-91
    B.5.5Fax number+33-(0)5-34-50-62-20
    B.5.6E-mailmohammed.zaim@pierre-fabre.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameLevomilnacipran (hydrochloride)
    D.3.2Product code F2695
    D.3.4Pharmaceutical form Prolonged-release capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNLevomilnacipran
    D.3.9.2Current sponsor codeF2695
    D.3.9.3Other descriptive nameLevomilnacipran
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameLevomilnacipran (hydrochloride)
    D.3.2Product code F2695
    D.3.4Pharmaceutical form Prolonged-release capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNLevomilnacipran
    D.3.9.2Current sponsor codeLevomilnacipran
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboCapsule, hard
    D.8.4Route of administration of the placeboOral use
    D.8 Placebo: 2
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboCapsule, hard
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Functionnal impairment after acute ischemic stroke
    Deficiencia Funcional tras el ictus isquémico agudo.
    E.1.1.1Medical condition in easily understood language
    Handicap in post stroke patients
    Minusvalía en pacientes tras el accidente cerebrovascular.
    E.1.1.2Therapeutic area Diseases [C] - Cardiovascular Diseases [C14]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 14.1
    E.1.2Level PT
    E.1.2Classification code 10061256
    E.1.2Term Ischaemic stroke
    E.1.2System Organ Class 10029205 - Nervous system disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To assess the effect of 3-month treatment with F2695 (75 mg OD) on improving functional recovery in patients with moderate to severe motor deficits after an ischemic stroke
    Evaluar el efecto de 3 meses de tratamiento con F2695
    (75 mg al día) para favorecer la recuperación funcional de pacientes con déficit motor moderado a
    grave por un ictus isquémico.
    E.2.2Secondary objectives of the trial
    To assess the effect of F2695 on:
    o Motor recovery,
    o Occurrence and recurrence of depression,

    To evaluate the safety and tolerability of F2695 in patients with ischemic stroke.
    Evaluar el efecto del F2695 sobre:
    - la recuperación motriz;
    - la incidencia y la reincidencia de la depresión.

    Evaluar la seguridad y la tolerabilidad del F2695 en pacientes con ictus isquémico.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Demographic Characteristics and Diagnostic criteria:
    To be included in the trial, patients admitted to stroke units should fulfil the following criteria:
    o Male or female patient, 18 to 80 years of age, inclusively,
    o Who had a confirmed acute ischemic stroke within the past 2 - 10 days , associated:
    o with an unilateral motor deficit (hemiparesis or hemiplegia),
    o with a National Institutes of Health stroke scale (NIHSS) motor score greater or equal to 5,
    o with a modified Rankin Scale (mRS) of 4 or 5,
    o Able and willing to comply with the site rehabilitation program requirements,
    o Woman of childbearing potential must have been using an effective method of contraception (defined as surgical or hormonal birth control, or intra-uterine device only), assessed by the investigator, for at least 2 months before selection in the study, and must accept to go on using it during the whole duration of the study and up to 1 month after the last dose of the study treatment, in order to avoid pregnancy while being exposed to the study treatment

    Ethical /legal considerations:
    o Signed written informed consent to take part in the study obtained from the patient. In case of impossibility for the patient to sign the consent form, the consent is to be witnessed by a third party completely independent from the investigator and the sponsor. This witness will have to sign the consent form and the patient will have to sign the consent form once his condition permits , before the end of the study.
    o Affiliated to a social security system, or is a beneficiary (if applicable in the national regulation).
    Características demográficas y diagnóstico:
    Para participar en el estudio, el paciente debe encontrarse ingresado en una unidad de ictus y reunir todos los criterios siguientes:
    o Sexo masculino o femenino y edad comprendida entre los 18 y los 80 años inclusive.
    o Ictus isquémico agudo confirmado en los últimos 2-10 días, asociado:
    - con un déficit motor unilateral (hemiparesia o hemiplejia);
    - con una puntuación motriz mayor o igual a 5 en la Escala del Ictus de los National Institutes of Health (NIHSS);
    - con una puntuación de 4 ó 5 en la Escala de Rankin modificada (mRS).
    o Capacidad y voluntad de ceñirse a los requisitos del programa de rehabilitación del centro.
    o En el caso de las mujeres en edad fértil, utilización de un método anticonceptivo eficaz (esterilización quirúrgica, anticonceptivos hormonales o dispositivo intrauterino), a juicio
    del investigador, durante al menos 2 meses antes de la selección y compromiso de continuar utilizándolo durante todo el estudio y hasta que transcurra un mes de la última dosis del tratamiento, a fin de prevenir el embarazo durante la exposición al medicamento.

    Aspectos ético-jurídicos:
    o Firma del documento de consentimiento informado para participar en el estudio. Si el paciente está incapacitado para firmarlo personalmente, el proceso de consentimiento
    deberá presenciarlo un testigo imparcial que sea totalmente ajeno al promotor y al equipo investigador. El testigo firmará en un primer momento el documento de consentimiento informado y el paciente lo firmará cuando se lo permita su estado, antes de que termine el estudio.
    o Afiliación a un régimen de la Seguridad Social o condición de beneficiario (según proceda en el sistema nacional de salud).
    E.4Principal exclusion criteria
    - Disease-related criteria:
    o Patient with motor sequelae from a previous stroke,
    o Patient with pre-existing or concomitant deficit that could interfere with testing or clinical assessments,
    o Patient with aphasia preventing correct evaluation of motor and / or depression scales,
    o Patient with severe post-stroke condition (NIHSS score >20),
    o Patient with active depressive episode (MADRS score of more than 18 and / or a Clinical Global Impression scale in depression - CGI - Depression > 3),
    o Patient with evidence of intra-cerebral haemorrhage on brain MRI or CT scan,
    o Patient needing carotid surgery within 3 months.

    - Previous or concomitant treatment-related criteria:
    o Patient having taken within the month preceding inclusion one or more of the following drugs:
    o antidepressant drugs belonging to the classes of SSRIs, SNRIs and TCAs (whatever the indication),
    o monoamine oxidase inhibitors or any other drug which may increase the risk of serotonin syndrome (tramadol, methylphenidate, triptans, propoxyphene, lithium...)
    o neuroleptic drugs,
    o alpha1-adrenoreceptor antagonists,
    o central nervous system stimulants (modafinil, methylphenidate, amphetamines...),
    o Patient with an history of intolerance or hypersensitivity to F2695, milnacipran or other SNRIs, SSRIs, or selective noradrenergic reuptake inhibitors,
    o Patient displaying criteria for psychoactive substance abuse or dependency (according to DSM-IV).

    - Patient-related criteria:
    o Patient with severe cognitive impairment or dementia,
    o Patient presents an acute coronary syndrome,
    o Patient presenting cardiac rhythm disorder (including
    tachyarrhythmia) in the 3 months preceding the inclusion,
    o Patient presenting uncontrolled arterial hypertension or symptomatic postural hypotension,
    o Patient with history of myocardial infarction in the preceding 3 months,
    o Patient unable to safely swallow capsules,
    o Patient presenting disability (mRS > 1) prior to the current stroke (rheumatological diseases, sequelaes of traumatic diseases or from previous stroke injury...),
    o Patient with the following abnormal clinical laboratory test results:
    - Liver function test values (aspartate aminotransferase and/or alanine aminotransferase) greater than 3 times the upper limit of normal,
    - An estimated glomerular filtration rate (eGFR) < 60ml/min/1,73m2
    o Patient with a history of coagulation or haemostasis disorders which the investigator deems incompatible with study implementation,
    o Patient with a history of narrow angle glaucoma,
    o Patients with a prior history of seizures/epilepsy (before the onset of stroke event),
    o Patient presenting with a severe acute or chronic disease which the investigator deems incompatible with study implementation. This includes evidence of malignancy or any significant or progressive disease (endocrine, respiratory, renal, hepatic, gastrointestinal, neurologic disease or infectious disease),
    o Patient liable not to comply with protocol instructions and/or with treatment (including rehabilitation therapy), in the investigator's opinion,
    o Male patients with history of obstructive voiding symptoms, including urinary retention,
    o For women patients:
    - pregnant, breast feeding or likely to become pregnant during the time of the study
    o women with childbearing potential not using effective contraception (defined as surgical or hormonal birth control, or intra-uterine device only).
    o positive serum ?-hCG pregnancy test at inclusion for females with childbearing potential.
    Criterios patológicos:
    o Secuelas motrices de un ictus anterior.
    o Déficit preexistente o concomitante que interfiera en las evaluaciones clínicas o los análisis de laboratorio.
    o Afasia que impida la correcta evaluación de las escalas de la función motriz o de la depresión.
    o Estado grave como consecuencia del ictus (NIHSS > 20).
    o Episodio depresivo activo (puntuación MADRS > 18 o puntuación > 3 en la escala de impresión clínica global [CGI] de la depresión).
    o Objetivación de hemorragia intracerebral en el TAC o la RMN encefálica.
    o Necesidad de cirugía de carótidas en los próximos 3 meses.

    Criterios relacionados con los tratamientos previos o concomitantes:
    o Tratamiento, en el mes anterior a la inclusión, con los fármacos siguientes:
    - antidepresivos de la clase de los ISRS, los ISRN y los tricíclicos (por cualquier indicación);
    - inhibidores de la monoamina-oxidasa o cualquier otro fármaco que acentúe el riesgo de síndrome serotoninérgico (tramadol, metilfenidato, triptanos, dextropropoxifeno, litio, etc.);
    - neurolépticos;
    - antagonistas del receptor adrenérgico alfa-1;
    - estimulantes del sistema nervioso central (modafinilo, metilfenidato, anfetaminas, etc.).
    o Antecedentes de intolerancia o hipersensibilidad al F2695, al milnaciprán o a otros ISRN, ISRS o inhibidores selectivos de la recaptación noradrenérgica.
    o Criterios de abuso o dependencia de sustancias psicoactivas (según el DSM-IV).

    Criterios relacionados con el paciente:
    o Deterioro cognitivo grave o demencia.
    o Síndrome coronario agudo.
    o Trastornos del ritmo cardíaco (incluida la taquiarritmia) en los 3 meses anteriores a la inclusión.
    o Hipertensión arterial incontrolada o hipotensión ortostática sintomática.
    o Antecedentes de infarto de miocardio en los últimos 3 meses.
    o Incapacidad de tragar cápsulas.
    o Discapacidad (mRS > 1) antes del ictus actual (reumatismos, secuelas de traumatismos o de un ictus anterior, etc.).
    o Las siguientes alteraciones analíticas:
    - valores de función hepática (concentración de aspartato-aminotransferasa o alaninaaminotransferasa) que tripliquen el límite superior de la normalidad;
    - índice de filtración glomerular estimado (IFGe) < 60 ml/min/1,73 m2.
    o Antecedentes de trastornos de la coagulación o de la hemostasia que el investigador estime incompatibles con la participación en el estudio.
    o Antecedentes de glaucoma de ángulo cerrado.
    o Antecedentes de convulsiones o epilepsia (antes del accidente cerebrovascular actual).
    o Enfermedad aguda o crónica grave que el investigador estime incompatible con la participación en el estudio; por ejemplo: neoplasia maligna o enfermedad degenerativa o importante (endocrina, respiratoria, renal, hepática, digestiva, neurológica o infecciosa).
    o Previsión de incumplimiento de las instrucciones del protocolo o del tratamiento (incluida la rehabilitación), a juicio del investigador.
    o En el caso de los varones, antecedentes de síntomas de obstrucción miccional, p. ej. retención urinaria.
    o En el caso de las mujeres:
    - embarazo, lactancia materna o posibilidad de concebir durante el estudio;
    - si son fértiles, no utilizar un método anticonceptivo eficaz (esterilización quirúrgica, anticonceptivos hormonales o dispositivo intrauterino);
    - positivo en la prueba del embarazo de la beta-hCG en suero en la selección.
    E.5 End points
    E.5.1Primary end point(s)
    The primary efficacy end-point is the primary criterion will be the response rate defined as the percentage of patients with a Modified Rankin Scale (mRS) less than or equal to 2 at Week 12.
    El criterio principal de valoración será la tasa de respuesta, definida como el porcentaje de pacientes con una puntuación menor o igual a 2 en la Escala de Rankin modificada (mRS) en la semana 12.
    E.5.1.1Timepoint(s) of evaluation of this end point
    The primary efficay end point will be measure at Week 12
    El criterio principal de valoración será medido en la Semana 12.
    E.5.2Secondary end point(s)
    Secondary efficacy criteria include:
    1) The change from baseline to Week 12 of the:
    - mRS score,
    - mean NIHSS total and motor scores,
    2) The percentage of patients with :
    - an NIHSS score less than or equal to 5 at Week 12,
    - at least one moderate to severe depressive episode (MADRS > 25 and or CGI-depression > 4) at Week 12.

    Safety end-points:
    1) percentage of patients reporting at least one adverse event (AE) in each group,
    2) physical examination, vital sign measurements
    3) electrocardiograms (ECGs),
    4) clinical laboratory values.
    Los Criterios secundarios de valoración de la eficacia incluyen:
    1) Variación en la semana 12, respecto al valor basal, de:
    - la puntuación de la mRS;
    - la puntuación media total y la puntuación motriz de la NIHSS.
    2) Porcentaje de pacientes con:
    - puntuación menor o igual a 5 en la NIHSS a la semana 12;
    - al menos un episodio depresivo moderado o grave (MADRS > 25 o CGI-depresión > 4) a la semana 12.

    Criterios de Seguridad:
    1) Porcentaje de pacientes que refieren al menos un acontecimiento adverso
    (AA) en cada grupo.
    2) Datos de las exploraciones físicas y constantes vitales.
    3) Electrocardiogramas (ECG).
    4) Análisis clínicos de laboratorio.
    E.5.2.1Timepoint(s) of evaluation of this end point
    The secondary efficacy endpoints will be measured at Week 12.

    The safety end points will be measured at each visit
    Los Criterios secundarios de valoración de la eficacia se medirán en la Semana 12.

    Los Criterios de seguridad se medirán en cada visita.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned12
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA72
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Belgium
    Czech Republic
    Denmark
    France
    Germany
    Hungary
    Italy
    Netherlands
    Portugal
    Russian Federation
    Spain
    Sweden
    Switzerland
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Last visit of last patient as per protocol
    Última visita del último paciente, según el protocolo.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months10
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months10
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 133
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 399
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state72
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 470
    F.4.2.2In the whole clinical trial 532
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Standard care for stroke
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2012-09-25
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2012-09-07
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2015-02-11
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Apr 19 22:46:47 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA